Shreyansh Singh

Shreyansh Singh

Auto-generated profile, based on publicly available information

Shreyansh Singh

Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh 201306, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2026 in Current Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSShreyansh Singh
Shreyansh Singh
MOMonika
Monika
RMRUPA MAZUMDER
RUPA MAZUMDER
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Introduction: Anxiety disorders have neurochemical imbalances, structural changes in the brain, and dysfunctional neurotransmitter systems. The challenge in treating these disorders is the complexity of the Blood-Brain Barrier (BBB) and the ineffectiveness of traditional pharmacological methods, which may not provide accurate targeting of drugs and could be toxic. Methodology: The literature study was performed to identify relevant studies on Stimuli-Responsive Drug Delivery Systems (SRDDS) and their uses in the treatment of anxiety. The major databases, including PubMed, Scopus, Web of Science, and Google Scholar, were thoroughly studied. Results: SRDDS had great potential in improving bioavailability, achieving targeted release, and reducing systemic side effects in the treatment of anxiety disorders. Responsive systems to internal and external stimuli helped improve drug penetration through the BBB and prolonged the effects. Discussion: The incorporation of SRDDS in the treatment of anxiety fills a major gap in the conventional delivery of drugs by ensuring a controlled release at the desired site. Although the interdisciplinary approach of nanotechnology, materials science, and neurobiology has helped advance the field, concerns about cost, reproducibility, and safety remain. Conclusion: SRDDS offers a new approach to managing anxiety by allowing for targeted, controlled, and flexible delivery of anxiolytics through the BBB. While most existing evidence is still at the preclinical level, ongoing investigations, the incorporation of biomarkers, and improvements in scalable manufacturing techniques could help turn these systems into effective, customized treatments for anxiety disorders.